Related Insights
REACH SVHC July Update: Regulatory Intelligence for Chemical Procurement Compliance
The anticipated July to August 2026 REACH SVHC candidate list update could introduce new notification obligations for chemical manufacturers, importers and downstream users. Procurement and compliance teams should prepare now to respond quickly when the revised candidate list is published.
CSRD and Chemical Supply Chain Due Diligence: How Ownership Transfers Affect Scope 3 Data
Supplier ownership changes can create unexpected challenges for Scope 3 emissions reporting under the Corporate Sustainability Reporting Directive. This guide explains how procurement and sustainability teams should manage supplier data continuity following ownership transfers.
The EU Green Deal's Chemical Strategy for Sustainability: What Has Been Retained and What Has Changed
The EU's Chemicals Strategy for Sustainability remains an important foundation for chemical regulation, but implementation has evolved alongside newer competitiveness initiatives. Here's what procurement professionals should understand for compliance planning in the second half of 2026.
Force Majeure Wind-Down in H1 2026: Legal and Commercial Reset for Chemical Supply Contracts
Force majeure declarations triggered by the Hormuz crisis are now entering a structured wind-down phase across chemical supply chains. Procurement and legal teams must formalise documentation to avoid pricing disputes, liability gaps and contract ambiguity in H2 2026.
TSCA 2026: Immediate Actions After Fee Authority Expiry
When the TSCA fee authority expires in 2026, chemical manufacturers, importers and compliance teams face a new set of obligations. This article outlines the urgent steps required to stay compliant, from PMN filing updates to EPA chemical review adjustments. Read on to ensure your operations remain uninterrupted.
Pharmaceutical Regulations 2026: FDA's Revised PFAS Reporting Rule Expected in June 2026
New PFAS reporting requirements are expected to reshape compliance obligations across the pharmaceutical supply chain. Manufacturers should begin assessing ingredients, excipients, packaging materials and supplier networks before reporting windows open.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.